Breaking News: Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing | Financial Buzz

Breaking News: Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has appointed Mr. Valentino Smith, MBA as Vice President of Marketing. Mr. Smith brings over ten years of marketing experience to Todos, including brick & mortar and digital marketing for consumer packaged goods, healthcare services & information, over-the-counter (OTC) supplement and pharmaceutical products. 

“I am very excited to be joining Todos, especially as the Company begins to market Tollovid and Tollovid Daily, and as the Company prepares to engage with regulatory agencies worldwide regarding Tollovir™, the Company’s oral antiviral drug candidate for COVID-19 is currently in a Phase 2 trial for hospitalized patients,” said Valentino Smith, MBA, Vice President of Marketing at Todos. “I see tremendous opportunity for growth and I’m looking forward to driving the effort going forward just as we are seeing a massive surge in the need for high throughput rapid turnaround SARS-CoV-2 PCR testing as the Omicron variant takes hold across the United States.”

Mr. Valentino joins Todos with over 10 years of marketing experience in healthcare. Most recently, Mr. Valentino was the Omni-Channel Engagement Lead for Novartis Oncology where he developed media plans and led the execution of global digital solutions for Piqray’s early launch. Prior to Novartis, Mr. Smith served as Associate Director of Global Marketing for Merck, where he drove scientific engagement plans with Medical Affairs by identifying new ways to interact and partner with healthcare professionals and various patient advocacy groups. Prior to Merck, Mr. Smith worked in various marketing roles at WebMD and McCann Healthcare / Grey Healthcare Group. Mr. Valentino is currently an Adjunct Assistant Professor of Marketing at Long Island University and received his undergraduate and MBA degrees from Long Island University.

Concurrent with this announcement, the Company retained the services of iiiNTENT, an artificial intelligence digital marketing software as a service (SAAS) to assist with the marketing of 3CL protease inhibitor dietary supplement immune support products Tollovid® and Tollovid Daily™.

“We are very excited to be partnering with Todos Medical on the pending marketing campaigns for Tollovid and Tollovid Daily,” said Chase Gibson, Co-CEO of iiiNTENT. “This appears to be an extremely timely product and we believe we can drive substantial traffic with high conversion rates given highly motivated personas we intend to target.”

“We are now in growth mode for our commercial products and services from our Tollovid & Tollovid Daily products to our COVID testing services that we are currently offering from our Provista Diagnostics CLIA/CAP laboratory,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Valentino’s extensive background in marketing key healthcare-based products at the highest levels has prepared him for the challenges in helping us engage with clients and customers for our diverse array of products & services that address key bottlenecks that currently exist in our healthcare system. We are also very excited about working with iiiNTENT to drive growth for our Tollovir brand of products, as we believe that could be a big driver of revenue growth heading into 2022.”

For more information on Provista’s parent company Todos Medical, please visit www.todosmedical.com. For more information on Provista Diagnostics’ CLIA/CAP certified lab please visit www.provistadx.com.

About Todos Medical Ltd. 

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.

Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.

Sponsored Content Release. Click for Full Disclosure

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.